PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.50%
Net income growth under 50% of CRVO's 171.19%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-31.48%
Both reduce yoy D&A, with CRVO at -12.31%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-66.70%
Negative yoy deferred tax while CRVO stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
10.78%
SBC growth while CRVO is negative at -14.01%. John Neff would see competitor possibly controlling share issuance more tightly.
-179.22%
Negative yoy working capital usage while CRVO is 92.24%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-302.85%
Negative yoy AP while CRVO is 88.74%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-91.10%
Negative yoy usage while CRVO is 131.63%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
10.78%
Some yoy increase while CRVO is negative at -189.59%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-32.84%
Negative yoy CFO while CRVO is 19.61%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-1.01%
Both yoy lines negative, with CRVO at -804.43%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1225.23%
We reduce yoy other investing while CRVO is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-1611.06%
Both yoy lines negative, with CRVO at -157741.02%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.